MedTrace Logo

Cytokine Hemoadsorption in ECMO Patients

NCT04901338 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2021-05-25

No results posted yet for this study

Summary

Cytokine hemoadsorption is a novel therapy used to improve outcome in critically ill patients with a dysregulated cytokine response and hemodynamic instability. Patients on extracorporeal membraneous oxygenation (ECMO) often develop severe systemic inflammatory response syndrome (SIRS). Cytokine removal using different types of hemoadsorption devices is believed to block the vicious circle of inflammation dysregulation when other basic therapeutic measures fail. To date there are very limited reports on ECMO and cytokine hemoadsorption combination therapy. The aim of this retrospective study is to evaluate feasibility and effectiveness of hemoadsorption in veno-arterial and veno-venous ECMO patients.

Conditions

  • SIRS
  • Cytokine Storm
  • Cardiogenic Shock
  • Cardiac Arrest
  • Septic Shock
  • ARDS, Human

Sponsors & Collaborators

  • University Medical Centre Ljubljana

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-01
Primary Completion
2021-01-31
Completion
2021-01-31

Countries

  • Slovenia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04901338 on ClinicalTrials.gov